Impact of Clinical Trial Participation vs Standard of Care on Outcomes in Patients With EGFR Wild-Type and ALK-Negative NSCLC
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Lung Cancer
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Survival benefit in EGFR-wild and ALK negative NSCLC patients who participate in clinical trials compared to standard-of-care: Propensity-matched analysis
Lung Cancer 2024 Mar 13;190(xx)107536, HA Jung, B Park, S Park, JM Sun, SH Lee, J Seok Ahn, MJ AhnFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.